Examkin

Question

Difficulty: HardRheumatology and Immunology

A 31-year-old man returns to the clinic for a follow-up regarding chronic lower back pain. He first developed the pain 1818 months ago. It is characteristically worse in the morning and improves with exercise. Three months ago, he was diagnosed with ankylosing spondylitis based on classic clinical findings and evidence of bilateral sacroiliitis on pelvic radiography. Over the past 3 months, he has undergone consecutive, continuous trials of naproxen and ibuprofen at maximum tolerated doses, along with a daily physical therapy regimen. Today, he reports no significant improvement in his symptoms, complaining of persistent spinal stiffness that lasts for up to 22 hours every morning. He denies any peripheral joint pain, swelling, eye redness, or gastrointestinal symptoms. Vital signs are within normal limits. Physical examination reveals restricted lumbar flexion and tenderness over the sacroiliac joints. Laboratory studies show an erythrocyte sedimentation rate of 45 mm/h45 \text{ mm/h} (Reference: <15 mm/h< 15 \text{ mm/h}) and a C-reactive protein of 22 mg/L22 \text{ mg/L} (Reference: <3 mg/L< 3 \text{ mg/L}). Which of the following is the most appropriate next step in the management of this patient's condition?

  1. A
    Add oral methotrexate
  2. B
    Prescribe a tapering dose of oral prednisone
  3. Initiate therapy with etanerceptAnswer
  4. D
    Add oral sulfasalazine
  5. E
    Obtain magnetic resonance imaging of the sacroiliac joints

Answer

Initiate therapy with etanercept
The correct action is to initiate a biologic agent, such as a tumor necrosis factor (TNF) alpha inhibitor (e.g., etanercept, adalimumab, infliximab) or an IL-17 inhibitor. This patient has active ankylosing spondylitis with purely axial involvement that has failed to improve after continuous, adequate trials of multiple nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs are the first-line pharmacotherapy for symptomatic relief; however, if disease activity remains high despite an adequate trial (typically at least 2-4 weeks each of two different NSAIDs), biologic disease-modifying antirheumatic drugs (DMARDs) are indicated to reduce inflammation, improve mobility, and potentially slow radiographic progression.

Step-by-Step Solution

1
Identify the patient's diagnosis and current disease phenotype.
The patient has confirmed ankylosing spondylitis with isolated axial symptoms (morning stiffness, limited lumbar flexion) and elevated inflammatory markers, with no peripheral joint involvement.
Understanding the clinical phenotype (axial versus peripheral) is necessary to guide therapeutic decisions in spondyloarthropathies.
2
Evaluate the patient's prior treatment and response.
He has failed continuous trials of two different NSAIDs (naproxen and ibuprofen) at maximum tolerated doses over a 3-month period, alongside physical therapy.
Guidelines require an adequate trial of at least two NSAIDs before escalating therapy for active ankylosing spondylitis.
3
Determine the appropriate escalation of therapy for purely axial disease.
A biologic DMARD, specifically a TNF-alpha inhibitor (e.g., etanercept) or an IL-17 inhibitor, is indicated.
Conventional synthetic DMARDs (methotrexate, sulfasalazine) are ineffective for axial disease. Biologics are the standard next step to control inflammation and improve functional status.

Key Concept

In patients with ankylosing spondylitis who have purely axial disease and fail to respond to continuous NSAID therapy, the most appropriate next step in management is the initiation of a TNF-alpha inhibitor (e.g., etanercept, adalimumab) or an IL-17 inhibitor. Conventional DMARDs (methotrexate, sulfasalazine) are ineffective for axial disease.
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic